Adriax®, NanoAlvand’s trusted solution in oncology with enhanced formulation for better safety and efficacy

NanoAlvand is proud to expand its oncology portfolio with the launch of Adriax®, a solution formulation of Doxorubicin Hydrochloride, available in 10 mg and 50 mg injectable vials.

Doxorubicin Hydrochloride is a cornerstone anthracycline chemotherapy agent, widely used in the treatment of various malignancies such as breast cancer, lymphomas, and leukemias. Recognized as an essential medicine, its efficacy is well-established across global cancer care protocols.

The newly introduced solution formulation by NanoAlvand offers improved stability, extended shelf life, and reduced risk of cardiotoxicity through optimized manufacturing processes. This innovation aligns with NanoAlvand’s ongoing mission to provide high-quality, safe, and effective cancer therapeutics to patients and healthcare professionals.

By delivering consistent performance and improved tolerability, Adriax® represents a significant step forward in enhancing chemotherapy outcomes.